UNIGE document Scientific Article
previous document  unige:143606  next document
add to browser collection
Title

T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial

Authors
Cosman, Felicia
Lewiecki, E Michael
Ebeling, Peter R
Hesse, Eric
Napoli, Nicola
Matsumoto, Toshio
Crittenden, Daria B
Rojeski, Maria
show hidden authors show all authors [1 - 11]
Published in Journal of Bone and Mineral Research. 2020, vol. 35, no. 7, p. 1333-1342
Abstract In the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) clinical trial (NCT01631214), 1 year of romosozumab followed by alendronate reduced the risk of vertebral and nonvertebral fractures compared to alendronate alone in women with prevalent fracture. We performed post hoc analyses of data from patients in ARCH (romosozumab, n = 1739; alendronate, n = 1726) who had a baseline BMD measurement and received at least one open-label alendronate dose. We evaluated 1-year mean BMD and corresponding T-score changes; proportions of patients achieving T-scores > -2.5 at the total hip (TH), femoral neck (FN), and lumbar spine (LS); and group differences in fracture rates after 12 months, while all participants were on alendronate.[...]
Keywords AlendronateBone Mineral DensityPostmenopausal OsteoporosisRomosozumabT-Score
Identifiers
PMID: 32445228
Full text
Structures
Research group Génétique des ostéoporoses (544)
Citation
(ISO format)
COSMAN, Felicia et al. T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial. In: Journal of Bone and Mineral Research, 2020, vol. 35, n° 7, p. 1333-1342. doi: 10.1002/jbmr.3996 https://archive-ouverte.unige.ch/unige:143606

121 hits

27 downloads

Update

Deposited on : 2020-10-28

Export document
Format :
Citation style :